The study looked at patients in federally qualified healthcare settings and examined the benefits, costs and cost-effectiveness of noninvasive screening tests when adherence to a multistep screening process reflects adherence rates in populations receiving care, according to a report from The American Journal of Managed Care.
The FDA recently approved blood-based screening for CRC.
The cohort represented a predominantly Hispanic or Latino population. The simulated population had low adherence rates to key screening steps, including first-step noninvasive testing (45%), second-step follow-up colonoscopy after abnormal noninvasive results (40%) and ongoing surveillance colonoscopy for patients with high-risk findings (80%).
The main outcomes were CRC incidence and mortality, life years gained and quality-adjusted life years gained relative to no screening, costs and net monetary benefit.
Fecal tests emerged as the most effective and cost-effective colorectal cancer screening strategy, yielding 121 life years gained per 1,000 screened individuals and a net monetary benefit of $5,883 per person.
In contrast, blood testing was the least effective strategy, producing only 23 life years gained per 1,000 individuals and a negative net monetary benefit.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.